Microbicide Trial Design Flexibility Supported At FDA Advisory Panel Meeting
This article was originally published in The Tan Sheet
Executive Summary
Microbicide researchers and health advocates urged FDA to adopt a flexible approach to the design of clinical studies on products for reducing HIV transmission during an August 20 meeting of the agency's Antiviral Drugs Advisory Committee in Bethesda, Md